← All claims

Sweeteners · Metabolic & Cardiometabolic · Gut & Microbiome

saccharin worsens glucose tolerance

Leans support Sweeteners

Part of: • saccharin

RefutedContestedStrong support
consensus score 0.52

Evidence ladder

How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."

Top evidence so far: Human trials (RCT / n-of-1)

MechanismIn-vitroAnimalObservationalRCTMeta-analysis

How the studies fall

3 support 0 contradict 0 tested null 5 mixed · 8 sources, 3 independent groups

What the evidence shows

Saccharin is the sweetener with the **strongest microbiome-mediated glucose-intolerance signal**: it was the lead compound in both Suez 2014 (mice + humans) and the Suez 2022 human RCT, where it impaired glycemic responses in susceptible individuals by altering the gut microbiome. As with the class claim, the effect is personalized and not universal — but for saccharin specifically the evidence is

The evidence (8)

SourceGradeStanceQualityFinding
Del Pozo et al.
2022 · Nutrients
observational mixed moderate Review: current evidence indicates saccharin (with sucralose) can influence gut-microbiota composition.
Suez et al.
2022 · Cell
RCT supports high Human RCT: saccharin impaired glycemic responses via microbiome changes in responsive individuals (lead compound).
Conz et al.
2023 · Nutrients
observational mixed moderate NNS–microbiota review: effects real but heterogeneous and personalized.
Ruiz-Ojeda et al.
2019 · Adv Nutr
observational mixed moderate Review: saccharin among the few sweeteners that measurably change human gut microbiota.
Gauthier et al.
2024 · Nutrition
observational supports moderate Human-trial review: saccharin (with sucralose) changed microbiota/glucose tolerance.
Suez et al.
2014 · Nature
animal supports moderate Nature: saccharin was the primary non-caloric sweetener inducing glucose intolerance via gut-microbiota changes (mice + human arm).
Al-Ishaq et al.
2023 · Nutrients
observational mixed low Sweeteners–microbiome review: saccharin among agents altering microbiota, clinical relevance debated.
Rathaus et al.
2024 · Mol Metab
animal mixed low Long-term NNS study: saccharin metabolic effects context-dependent.

Disagree, or know a study we missed?

We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.

📚 Suggest a study ⚑ Flag / request reclassification

Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).

Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.